Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats

Arribas, 2006, Elastic fibres and vascular structure in hypertension, Pharmacol. Ther., 111, 771, 10.1016/j.pharmthera.2005.12.003 Asanuma, 2003, Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells, Am. J. Physiol., Heart Circ. Physiol., 284, H1778, 10.1152/ajpheart.00494.2002 Borghi, 2005, Lercanidipine in hypertension, Vasc. Health Risk Manage., 1, 173 Bouvet, 2005, Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition, Hypertension, 45, 432, 10.1161/01.HYP.0000154680.44184.01 Castro, 2004, Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms, Eur. J. Pharmacol., 498, 189, 10.1016/j.ejphar.2004.07.051 Castro, 2008, Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats, Atherosclerosis, 198, 320, 10.1016/j.atherosclerosis.2007.10.011 Cau, 2008, Dose-dependent beneficial hemodynamic effects of BAY 41–2272 in a canine model of acute pulmonary thromboembolism, Eur. J. Pharmacol., 581, 132, 10.1016/j.ejphar.2007.11.030 Chesler, 1999, Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo, Am. J. Physiol., 277, H2002 Cohuet, 2006, Mechanisms of target organ damage caused by hypertension: therapeutic potential, Pharmacol. Ther., 111, 81, 10.1016/j.pharmthera.2005.09.002 Cominacini, 2003, Antioxidant activity of different dihydropyridines, Biochem. Biophys. Res. Commun., 302, 679, 10.1016/S0006-291X(03)00158-X Dao, 2001, Norepinephrine-induced aortic hyperplasia and extracellular matrix deposition are endothelin-dependent, J. Hypertens., 19, 1965, 10.1097/00004872-200111000-00006 Fernandez-Patron, 1999, Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor, Circ. Res., 85, 906, 10.1161/01.RES.85.10.906 Fernandez-Patron, 2000, Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction, Circ. Res., 87, 670, 10.1161/01.RES.87.8.670 Flamant, 2007, Role of matrix metalloproteinases in early hypertensive vascular remodeling, Hypertension, 50, 212, 10.1161/HYPERTENSIONAHA.107.089631 Galis, 2002, Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly, Circ. Res., 90, 251, 10.1161/res.90.3.251 Gerlach, 2005, Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities, Anal. Biochem., 344, 147, 10.1016/j.ab.2005.04.038 Gerlach, 2007, Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma, Clin. Biochem., 40, 119, 10.1016/j.clinbiochem.2006.10.007 Griendling, 2003, Oxidative stress and cardiovascular injury: Part II: animal and human studies, Circulation, 108, 2034, 10.1161/01.CIR.0000093661.90582.c4 Grote, 2003, Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species, Circ. Res., 92, e80, 10.1161/01.RES.0000077044.60138.7C Incandela, 2001, Oxygen-free radical decrease in hypertensive patients treated with lercanidipine, Int. Angiol., 20, 136 Lerman, 2005, Animal models of hypertension: an overview, J. Lab. Clin. Med., 146, 160, 10.1016/j.lab.2005.05.005 Martinez, 2004, Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator, Biochem. J., 383, 413, 10.1042/BJ20040920 Martinez, 2006, Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension, J. Cardiovasc. Pharmacol., 47, 117, 10.1097/01.fjc.0000196241.96759.71 Mason, 2003, Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine, Arterioscler. Thromb. Vasc. Biol., 23, 2155, 10.1161/01.ATV.0000097770.66965.2A Moreau, 2003, Role of endothelins in animal models of hypertension: focus on cardiovascular protection, Can. J. Physiol. Pharm., 81, 511, 10.1139/y03-015 Nelson, 2004, Mitochondrial redox control of matrix metalloproteinases, Free Radic. Biol. Med., 37, 768, 10.1016/j.freeradbiomed.2004.06.008 Prandin, 2007, Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: a prospective evaluation, Clin. Exp. Hypertens., 29, 553, 10.1080/10641960701744061 Ra, 2007, Control of matrix metalloproteinase catalytic activity, Matrix Biol., 26, 587, 10.1016/j.matbio.2007.07.001 Rachmani, 2002, Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study, Clin. Pharmacol. Ther., 72, 302, 10.1067/mcp.2002.127110 Raffetto, 2008, Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease, Biochem. Pharmacol., 75, 346, 10.1016/j.bcp.2007.07.004 Rodrigues, 2008, Vitamin C improves the effect of a new nitric oxide donor on the vascular smooth muscle from renal hypertensive rats, Nitric Oxide, 18, 176, 10.1016/j.niox.2007.12.002 Sabbatini, 2000, Nephroprotective effect of treatment with calcium channel blockers in spontaneously hypertensive rats, J. Pharmacol. Exp. Ther., 294, 948 Souza-Costa, 2005, L-arginine attenuates acute pulmonary embolism-induced increases in lung matrix metalloproteinase-2 and matrix metalloproteinase-9, Chest, 128, 3705, 10.1378/chest.128.5.3705 Souza-Costa, 2007, Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9, Crit. Care Med., 35, 239, 10.1097/01.CCM.0000251638.67104.C3 Souza-Tarla, 2005, Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities, Clin. Biochem., 38, 410, 10.1016/j.clinbiochem.2005.02.010 Taddei, 2001, Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients, J. Hypertens., 19, 1379, 10.1097/00004872-200108000-00005 Taddei, 2002, Effects of antihypertensive drugs on endothelial dysfunction: clinical implications, Drugs, 62, 265, 10.2165/00003495-200262020-00003 Taddei, 2003, Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension, Hypertension, 41, 950, 10.1161/01.HYP.0000063361.70525.3C Watts, 2007, Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats, Am. J. Physiol., Heart Circ. Physiol., 292, H2438, 10.1152/ajpheart.00900.2006 Yasmin, 2005, Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness, Arterioscler. Thromb. Vasc. Biol., 25, 372, 10.1161/01.ATV.0000151373.33830.41 Yue, 2004, Different effects of calcium channel blockers on matrix metalloproteinase-2 expression in cultured rat cardiac fibroblasts, J. Cardiovasc. Pharmacol., 44, 223, 10.1097/00005344-200408000-00012